Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
GAMCO INVESTORS, INC. ET AL GDL Gdl Fund 13D/A 23.39% 2y
GAMCO INVESTORS, INC. ET AL GGZ Gabelli Global Small & Mid Cap Value Trust 13D/A 31.93% 2y
Portolan Capital Management, LLC INVE INVE Technologies, Inc. 13G 5.54% 2y
NEEDHAM INVESTMENT MANAGEMENT LLC TDUP ThredUp Inc. 13G 5.45% 2y
PERCEPTIVE ADVISORS LLC DTIL Precision Biosciences Inc 13G 7.9% 2y
ADAR1 Partners, LP QTTB Q32 Bio Inc. 13G 5.4% 2y
Mitchell P. Kopin BBLG Bone Biologics Corp 13G 9.99% 2y
Kissei Pharmaceutical Co., Ltd. CGON CG Oncology, Inc. 13G 5.3% 2y
Erik E. and Edith H. Bergstrom Foundation ADX Adams Diversified Equity Fund, Inc. 13G/A 5.5% 2y
Thomas Meyer CYTOF Altamira Therapeutics Ltd. 13D/A 1.2% 2y
VITO GARFI SQFT Presidio Property Trust, Inc. 13D/A 4.1% 2y
SIT INVESTMENT ASSOCIATES INC PIM Franklin Master Intermediate Income Trust 13D/A 44.85% 2y
5AM Partners VII, LLC SKYE Skye Bioscience, Inc. 13D/A 40% 2y
Kimmeridge Energy Management Company, LLC SBOW SilverBow Resources, Inc. 13D/A 12.9% 2y
GAMCO INVESTORS, INC. ET AL HARP Harpoon Therapeutics, Inc. Common Stock 13D/A 0% 2y
Deutsche Telekom AG TMUS T-Mobile US, Inc. 13D/A 57.6% 2y
Waterton Global Resource Management, Inc. IAUX i-80 Gold Corp. 13G/A 4.6% 2y
Saba Capital Management, L.P. BCAT BlackRock Capital Allocation Term Trust 13D/A 15.2% 2y
Antofagasta plc BVN Buenaventura Mining Co Inc 13D/A 18.9% 2y
Saba Capital Management, L.P. IGA Voya Global Advantage & Premium Opportunity Fund 13D/A 6.78% 2y
Saba Capital Management, L.P. NQP NUVEEN PENNSYLVANIA QUALITY MUNICIPAL INCOME FUND 13D/A 12.9% 2y
NSV Investments I, L.P. VTYX Ventyx Biosciences, Inc. Common Stock 13D/A 12% 2y
Artal International S.C.A. LXRX Lexicon Pharmaceuticals, Inc. 13D/A 47.7% 2y
Camac Partners, LLC ABCP AmBase Corp 13D/A 5.5% 2y
Don R. Daseke PROF Profound Medical Corp. 13G/A 4.5% 2y
STRONG RICHARD S CVU Cpi Aerostructures Inc 13G 5% 2y
Juniper Investment Company, LLC LINC Lincoln Educational Services Corp 13D/A 11.4% 2y
Denver J. Smith IVFH Innovative Food Holdings Inc 13D/A 8.1% 2y
AbbVie Biotechnology Ltd. CARM Carisma Therapeutics Inc. 13G 6.8% 2y
DANIEL E. STONE SCNI Scinai Immunotherapeutics Ltd. 13D 12.96% 2y
GAMCO INVESTORS, INC. ET AL INVX Innovex International, Inc. 13D/A 6.38% 2y
GAMCO INVESTORS, INC. ET AL CYT Cyteir Therapeutics, Inc. Common Stock 13D/A 4.2% 2y
George P. Bauer ASLE AerSale Corp 13D/A 7.5% 2y
Saba Capital Management, L.P. GRX Gabelli Healthcare & WellnessRx Trust 13G 5.1% 2y
CYRUS CAPITAL PARTNERS, L.P. ICMB Investcorp Credit Management BDC, Inc. 13D/A 4.7% 2y
Warren B. Kanders CLAR Clarus Corp 13D/A 16.7% 2y
Fund 1 Investments, LLC CTRN Citi Trends Inc 13D/A 18.1% 2y
JAB BevCo B.V. KDP Keurig Dr Pepper Inc. 13D/A 21.9% 2y
Greenhaven Road Investment Management, L.P. PAR Par Technology Corp 13G 5.9% 2y
Pinetree Capital Ltd. TBRG TruBridge, Inc. 13D 7.5% 2y
Richard L. Soloway NSSC Napco Security Technologies, Inc 13D/A 4.8% 2y
Kent Lake Capital LLC MDRX Veradigm Inc. Common Stock 13G 5.54% 2y
Davidson Kempner Capital Management LP VCSA Vacasa, Inc. Class A Common Stock 13G 8.06% 2y
Haim Shani CLBT Cellebrite DI Ltd. 13G/A 10.8% 2y
STOCK YARDS BANK & TRUST CO SYBT Stock Yards Bancorp, Inc. 13G/A 5.2% 2y
Standard General L.P. BALY Bally's Corp 13D/A 23.2% 2y
Independence Energy Aggregator L.P. CRGY Crescent Energy Co 13D/A 25.4% 2y
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP CMMB Chemomab Therapeutics Ltd. 13D/A 16% 2y
MERCK & CO., INC. PAND Pandion Therapeutics Inc. Common Stock 13D/A 100% 2y
Jacobsen Per A. BLIN Bridgeline Digital, Inc. 13G/A 7.2% 2y